论文部分内容阅读
目的:探究和分析布地奈德混悬液雾化吸入联合阿奇霉素治疗小儿支原体肺炎的临床疗效和安全性。方法:选取我院自2013年4月至2015年4月收治的60例支原体肺炎的患儿,采取随机数字表法分为实验组和对照组,每组各30例。实验组在采用布地奈德混悬液雾化吸入的基础上加用阿奇霉素进行治疗,对照组仅采用阿奇霉素进行治疗。对比两组患儿的临床疗效及不良反应。结果:实验组总有效29例,总有效率为96.7%,对照组总有效21例,总有效率为70.0%,两组总有效率存在显著差异(P<0.05)。实验组不良反应3例,不良反应发生率为10.0%,对照组不良反应5例,不良反应发生率为16.7%,两组不良反应发生率相比无明显差异(P>0.05)。结论:采用布地奈德混悬液雾化吸入联合阿奇霉素治疗小儿支原体肺炎临床疗效显著,不良反应较少,安全性较高,值得推广。
Objective: To investigate and analyze the clinical efficacy and safety of inhalation of budesonide suspension combined with azithromycin in the treatment of mycoplasma pneumonia in children. Methods: Sixty children with mycoplasma pneumonia who were admitted to our hospital from April 2013 to April 2015 were randomly divided into experimental group and control group, with 30 cases in each group. The experimental group was treated with azithromycin on the basis of inhalation of budesonide suspension and the control group only treated with azithromycin. The clinical efficacy and adverse reactions of two groups were compared. Results: The total effective rate of experimental group was 29, the total effective rate was 96.7%. The total effective rate of control group was 21 and the total effective rate was 70.0%. There was significant difference between the two groups (P <0.05). Three cases of adverse reactions in the experimental group, the incidence of adverse reactions was 10.0%, 5 cases of adverse reactions in the control group, the incidence of adverse reactions was 16.7%. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The use of budesonide aerosol inhalation combined azithromycin treatment of children with mycoplasma pneumonia clinical significant effect, less adverse reactions, high safety, it is worth promoting.